112 related articles for article (PubMed ID: 25400055)
1. [Effects of rosuvastatin on arterial stiffness in hyperlipidemia patients].
Wang P; Liu Y; Wang Z; Wang Z; Zhao N; Ye H; Ren L
Zhonghua Yi Xue Za Zhi; 2014 Aug; 94(31):2452-4. PubMed ID: 25400055
[TBL] [Abstract][Full Text] [Related]
2. Effects of rosuvastatin vs. simvastatin/ezetimibe on arterial wall stiffness in patients with coronary artery disease.
Liu B; Che W; Yan H; Zhu W; Wang H
Intern Med; 2013; 52(24):2715-9. PubMed ID: 24334573
[TBL] [Abstract][Full Text] [Related]
3. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
4. Low-dose rosuvastatin improves the functional and morphological markers of atherosclerosis in asymptomatic postmenopausal women with dyslipidemia.
Igase M; Kohara K; Tabara Y; Nagai T; Ochi N; Kido T; Ochi M; Miki T
Menopause; 2012 Dec; 19(12):1294-9. PubMed ID: 22850442
[TBL] [Abstract][Full Text] [Related]
5. Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial.
Tam LS; Li EK; Shang Q; Tomlinson B; Lee VW; Lee KK; Li M; Kuan WP; Li TK; Tseung L; Yip GW; Freedman B; Yu CM
Scand J Rheumatol; 2011 Nov; 40(6):411-21. PubMed ID: 21867445
[TBL] [Abstract][Full Text] [Related]
6. Relationships between use of statins and arterial stiffness in normotensive and hypertensive patients with coronary artery disease.
Wang ZG; Chen BW; Lü NQ; Cheng YM; Dang AM
Chin Med J (Engl); 2013 Aug; 126(16):3087-92. PubMed ID: 23981617
[TBL] [Abstract][Full Text] [Related]
7. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A
Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801
[TBL] [Abstract][Full Text] [Related]
8. Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high risk patients.
Egede R; Jensen LO; Hansen HS; Antonsen L; Hansen KN; Junker A; Thayssen P
Int J Cardiol; 2012 Jul; 158(3):376-9. PubMed ID: 21349594
[TBL] [Abstract][Full Text] [Related]
9. Low-dose rosuvastatin improves arterial stiffness in high-risk Japanese patients with dyslipdemia in a primary prevention group.
Hongo M; Kumazaki S; Izawa A; Hidaka H; Tomita T; Yazaki Y; Kinoshita O; Ikeda U
Circ J; 2011; 75(11):2660-7. PubMed ID: 21857142
[TBL] [Abstract][Full Text] [Related]
10. Sustained Improvement of Arterial Stiffness and Blood Pressure after Long-Term Rosuvastatin Treatment in Patients with Inflammatory Joint Diseases: Results from the RORA-AS Study.
Ikdahl E; Rollefstad S; Hisdal J; Olsen IC; Pedersen TR; Kvien TK; Semb AG
PLoS One; 2016; 11(4):e0153440. PubMed ID: 27093159
[TBL] [Abstract][Full Text] [Related]
11. Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering?
Milionis HJ; Gazi IF; Filippatos TD; Tzovaras V; Chasiotis G; Goudevenos J; Seferiadis K; Elisaf MS
Angiology; 2005; 56(5):585-92. PubMed ID: 16193198
[TBL] [Abstract][Full Text] [Related]
12. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
[TBL] [Abstract][Full Text] [Related]
13. Comparision of effects of rosuvastatin versus atorvastatin treatment on plasma levels of asymmetric dimethylarginine in patients with hyperlipidemia having coronary artery disease.
Kurtoglu E; Balta S; Sincer I; Altas Y; Atas H; Yilmaz M; Korkmaz H; Erdem K; Akturk E; Demirkol S; Can C
Angiology; 2014 Oct; 65(9):788-93. PubMed ID: 24163120
[TBL] [Abstract][Full Text] [Related]
14. Effect of two intensive statin regimens on progression of coronary disease.
Nicholls SJ; Ballantyne CM; Barter PJ; Chapman MJ; Erbel RM; Libby P; Raichlen JS; Uno K; Borgman M; Wolski K; Nissen SE
N Engl J Med; 2011 Dec; 365(22):2078-87. PubMed ID: 22085316
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis--a prospective case-series study.
Timár O; Szekanecz Z; Kerekes G; Végh J; Oláh AV; Nagy G; Csiki Z; Dankó K; Szamosi S; Németh Á; Soltész P; Szücs G
Arthritis Res Ther; 2013; 15(5):R105. PubMed ID: 24008003
[TBL] [Abstract][Full Text] [Related]
16. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
[TBL] [Abstract][Full Text] [Related]
17. Rosuvastatin--a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients.
Schuster H
Cardiology; 2003; 99(3):126-39. PubMed ID: 12824720
[TBL] [Abstract][Full Text] [Related]
18. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
[TBL] [Abstract][Full Text] [Related]
19. Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia.
Gliozzi M; Walker R; Muscoli S; Vitale C; Gratteri S; Carresi C; Musolino V; Russo V; Janda E; Ragusa S; Aloe A; Palma E; Muscoli C; Romeo F; Mollace V
Int J Cardiol; 2013 Dec; 170(2):140-5. PubMed ID: 24239156
[TBL] [Abstract][Full Text] [Related]
20. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.
Kostapanos MS; Milionis HJ; Lagos KG; Rizos CB; Tselepis AD; Elisaf MS
Eur J Pharmacol; 2008 Aug; 590(1-3):327-32. PubMed ID: 18585701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
